Netscientific PLC said its subsidiary ProAxsis had completed the development and evaluation of an AstraZeneca COVID-19 antibody test with "impressive performance evaluation results”.
Work carried out by Professor Tara Moore of the Ulster University, analysing over 1,100 clinical serology samples, showed the assay delivered “exceptional levels of sensitivity and specificity” of 100% and 99.3% respectively.
Diversified Energy Company PLC (LSE:DEC, OTCQX:DECPF) (DEC) chief executive Rusty Hutson told investors he’s “pleased with the progress” as the firm’s first-quarter trading update confirmed production averaging 136,000 barrels oil equivalent per day.
During the quarter, DEC acquired further producing assets in its ‘central region’, picking up wells in East Texas, along with a deal for midstream and processing facility assets in the region, whilst its Appalachian operations were bolstered with an acquisition of a second well-plugging company.
Genflow Biosciences PLC (LSE:GENF) said it had made excellent strategic progress since its float in January.
It said its pre-clinical programmes remain on track with human trials expected to get underway in around two years.
Pantheon Resources PLC (AIM:PANR, OTC:PTHRF) told investors it has formally executed contracts for the Nabors 105AC drill rig which will drill the Alkaid-2 well on Alaska's North Slope later this year.
Alkaid-2 is currently slated for spudding in July and is planned to be a horizontal well that will undergo long-term production testing.
Empire Metals Ltd (AIM:EEE) has released assay results of its diamond drill programme at the Eclipse gold project in Western Australia.
The drill programme was the second carried out by Empire at Eclipse and was designed to gather further geological and structural information on the mineralised shear and to test for lodes below the gold-depleted zone of weathering.
Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) has been given the green light by regulators in the US and Finland to begin an early-stage clinical trial of its immuno-oncology drug candidate.
Bexmarilimab will be used alongside the standard-of-care treatments in people with blood cancers such as relapsed acute myeloid leukaemia, myelodysplastic syndrome, and chronic myelomonocytic leukaemia.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) held its AGM in Subiaco, Western Australia, at which shareholders approved all but one put forward resolutions.
Approved were the appointments and reappointments of directors Joanne Kendrick, Philip Byrne, and Dr Stephen Staley. In addition, shareholders approved the adoption of company’s remuneration report, they ratified the issue of shares to contractor Elko, as well as the issue of placing shares and share options to brokers Euroz Hartleys, Cenkos and Inyati Capital.
Shareholder did not approve a mandate allowing management to issue further new equity, equal to 10% of the issued capital, without a further shareholder vote of approval.